• Khan Sharun, Ruchi Tiwari, Mohd Iqbal Yatoo, Shailesh Kumar Patel, Senthilkumar Natesan, Jaideep Dhama, Yashpal S Malik, Harapan Harapan, Raj Kumar Singh, and Kuldeep Dhama.
• Division of Surgery, ICAR-Indian Veterinary Research Institute , Izatnagar, Uttar Pradesh, India.
• Expert Opin Biol Ther. 2020 Sep 1; 20 (9): 1033-1046.

IntroductionCoronavirus disease 2019 (COVID-19) has spread to several countries globally. Currently, there is no specific drug or vaccine available for managing COVID-19. Antibody-based immunotherapeutic strategies using convalescent plasma, monoclonal antibodies (mAbs), neutralizing antibodies (NAbs), and intravenous immunoglobulins have therapeutic potential.Areas CoveredThis review provides the current status of the development of various antibody-based immunotherapeutics such as convalescent plasma, mAbs, NAbs, and intravenous immunoglobulins against COVID-19. The review also highlights their advantages, disadvantages, and clinical utility for the treatment of COVID-19 patients.Expert OpinionIn a pandemic situation such as COVID-19, the development of new drugs should focus on and expedite the strategies where safety and efficacy are proven. Antibody-based immunotherapeutic approaches such as convalescent plasma, intravenous immunoglobulins, and mAbs have a proven record of safety and efficacy and are in use for decades. Some of them are already being used to manage COVID-19 patients and found to be useful. However, the mAbs with virus neutralization potential is the need of the hour during this COVID-19 pandemic to be more specific and virus targeted. The research and investment need to be accelerated to bring them into clinical use for prophylactic and therapeutic purposes against COVID-19.

34 keywords...

hide…